Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 10 January 2025, 10:37 HKT/SGT
Share:
    

Source: NEC Corporation
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field
- Aiming to realize the promises of precision medicine for cancer patients -

TOKYO, Jan 10, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding (MoU) for a joint marketing partnership to develop and expand artificial intelligence/deep learning (AI/DL)-based analytical platforms in the field of digital pathology(1). Through this partnership, the two companies aim to promote precision medicine for cancer patients and contribute to the advancement of the healthcare industry.

Background

Precision medicine, in which more effective treatments with fewer potential side effects are selected based on each patient's unique characteristics and disease profile, is becoming increasingly prevalent. In pathology diagnostics(2), the use of AI/DL algorithms to analyze digital pathology images is being explored to identify pathological biomarkers(3) that can stratify patients and facilitate the selection of the most patient-tailored and promising treatments and drugs.

Objectives of the Partnership

As a social value creation company focused on solving various societal issues through advanced technologies, NEC has positioned healthcare and life sciences as a core pillar of its growth strategy. With a strong foundation in image analysis and other AI technologies, NEC has a long history of providing medical information systems such as electronic medical records to healthcare institutions. Additionally, NEC has acquired a license for manufacturing and marketing Class I medical devices in Japan, demonstrating expertise in regulatory approval processes for medical devices, including AI/DL-based digital pathology systems.

Biomy, which aims to realize personalized medicine through pathological AI technology, has developed DeepPathFinder™,(4), a proprietary, cloud-based, AI/DL automated digital pathology analytical platform. This platform automatically analyzes digital pathology images to classify cell and tissue types in specific regions and offers the unique ability to detect immune cells such as lymphocytes and plasma cells(5) from hematoxylin and eosin (H&E)-stained images6 only along with spatial biology features. It also quantifies characteristics related to drug efficacy and prognosis. By leveraging DeepPathFinder™, the efficiency and accuracy of analyses in the field of digital pathology can be dramatically enhanced.

This partnership integrates the cutting-edge AI technologies developed by NEC and Biomy with the primary objectives to enhance the DeepPathFinder™ platform for discovering new pathological biomarkers through AI/DL-based digital pathology image analysis, leverage data derived from pathological images, and support precision medicine and treatment planning, particularly in the field of cancer care. The resulting AI/DL-driven pathological biomarker discovery tool will then be offered to pharmaceutical/biotech companies and academia through the provision of the following:

  1. An automated digital pathology platform for independently exploring pathological biomarkers from pathology images.
  2. Full-fledged digital pathological biomarker discovery services offered through partnerships with NEC and Biomy.
  3. Guidance and support for obtaining regulatory approval for medical devices utilizing the newly discovered pathological biomarkers.

Future Developments

By advancing next-generation AI/DL-based pathology analysis platforms and promoting the use of the newly developed pathological biomarkers in clinical settings, NEC and Biomy aim to contribute significantly to the future of medical care and to deliver the promises of precision medicine to cancer patients.

(1) Digital pathology: A field involving the digitization and computational analysis of pathology slides.
(2) Pathology diagnostics: The study and diagnosis of disease through the examination of organs, tissues, cells, and bodily fluids.
(3) Pathological biomarkers: Biological markers identifiable through pathology that can indicate disease states, stratify patients, and predict responses to treatment. In this press release, biomarkers identified based on morphological features of pathological images are referred to as "pathological biomarkers."
(4) DeepPathFinder™: This platform is for research use only, not for clinical use.
(5) Lymphocytes and plasma cells: Lymphocytes are a type of white blood cell with immune-related functions, categorized into T cells, B cells, and NK cells. Additionally, plasma cells are a mature stage of B cells that produce antibodies and play a key role in attacking cancer cells, providing insights into individual immune responses and tumor characteristics. This evaluation helps determine the effectiveness of immunotherapies or specific treatments and contributes to the selection of the most suitable patients for clinical trials and treatment strategies for patients, making personalized and precision medicine a reality.(6) Hematoxylin and eosin (H&E) staining: This is a fundamental staining method always performed on tissue specimens in pathological histological diagnosis in combination with a light microscope.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com




Topic: Press release summary
Source: NEC Corporation

Sectors: Artificial Intel [AI]
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Sept 30, 2025 18:52 HKT/SGT
Ouribank Signs Agreement with NEC to Implement AI-Native Data Center and Campus Network from HPE Juniper Networking for Enhanced Operational Efficiency
Sept 29, 2025 15:24 HKT/SGT
NEC Releases Third Edition of TNFD Report
Sept 26, 2025 20:20 HKT/SGT
NEC Launches 25Gb/s SFP28 Bi-directional Optical Transceiver Capable of 80km Transmission
Sept 24, 2025 13:43 HKT/SGT
Meta, SoftBank Corp., IPS, TM, XLSmart, and NEC to build the Candle Submarine Cable System, Intra Asia, 24-Fiber Pair Optical Submarine Cable, Connecting Japan to Singapore
Sept 19, 2025 18:00 HKT/SGT
MOTER Technologies and NEC Form Strategic Capital Alliance to Advance the Future of Mobility Through Digital Innovation
Sept 16, 2025 13:00 HKT/SGT
NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2025"
Sept 12, 2025 14:08 HKT/SGT
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 5, 2025 10:20 HKT/SGT
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sept 4, 2025 10:15 HKT/SGT
NEC to begin proof of concept for early earthquake detection and analysis in Colombia
Aug 27, 2025 21:57 HKT/SGT
NEC develops AI technology for digitalizing work tasks without the need for pre-training and utilizing video from multiple cameras covering wide area worksites
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: